Website www.betapharma.com Founded 1996 | Headquarters Princeton | |
Beta Pharma, Inc. is an emerging American pharmaceutical company based out of Princeton, NJ, dedicated to the discovery, development, and commercialization of innovative late-stage therapies targeting oncology. Beta Pharma specializes in personalized medicine by developing new chemical entity (NCE) drugs that target specific genetic mutations.
Contents
History
In 1996, Beta Chemicals was founded in Science Park at Yale University as a contract research organization that provided custom synthesis to biotechnology and pharmaceutical companies. Two years later, it was renamed Beta Pharma, Inc. when the company started its first drug discovery project. Profits from the CRO business helped to fund the young company’s new drug discovery projects, which soon found success in oncology drugs.
Product Pipeline
The first anti-cancer compound, icotinib, was identified and patented in 2003. A joint venture between Beta Chemicals and Zheijang Betta Pharmaceuticals Ltd, in China was formed and icotinib hydrochloride was licensed to Zheijang Betta Pharmaceuticals Ltd for further development. Currently, Beta Pharma, Inc. retains exclusive global rights to icotinib outside of China.
Beta Pharma was founded on identifying highly specific therapeutics to treat a variety of biomarker-driven cancers. They prioritize projects based on scientific understanding and clinical need and continue to make significant efforts to develop NCEs targeting advanced lung, breast, and pancreatic indications.
Locations
Beta Pharma, Inc. is developing a presence in the northeast region of the US; the corporate office is located in Princeton, NJ, a research and development facility is located in Monmouth Junction, NJ, and a custom chemical synthesis laboratory in Branford, CT.